Pamela Drullinsky

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · The Lancet Oncology · 2021 · 349 citations

Medicine, Oncology, Pharmacology +17

Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.

Monika Engelhardt, Pamela Drullinsky, J G Guillem et al. · PubMed · 1997 · 192 citations

Medicine, Molecular Biology, Oncology +17

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial

Susan Dent, Javier Cortés, Young‐Hyuck Im et al. · Annals of Oncology · 2020 · 163 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) <i>v</i> FULV in patients (pts) with estrogen receptor (ER)-positive, <i>PIK3CA</i> -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

José Baselga, Susan Dent, Javier Cortés et al. · Journal of Clinical Oncology · 2018 · 140 citations

Medicine, Oncology, Pharmacology +16

Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.

Monika Engelhardt, Karen L. MacKenzie, Pamela Drullinsky et al. · PubMed · 2000 · 138 citations

Medicine, Hematology, Molecular Biology +16